Experimental cell therapy offers hope for patients exhausting all treatment options
NCT ID NCT07453836
Summary
This early-stage study is testing whether a new cell therapy called YTS109 is safe and might help adults with autoimmune hemolytic anemia who have not improved after trying at least three other treatments. Researchers will give patients different doses of the modified cells to find the safest amount and see if it helps control their disease. The study will also track how the body processes the cells and whether they help rebuild healthy blood cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing GoBroad Boren Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.